GO:0003245 cardiac muscle tissue growth involved in heart morphogenesis: Developmental Growth, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0003245 describes the developmental growth of cardiac muscle tissue that contributes to the shaping of the heart, a biological process distinct from adult cardiac hypertrophy.
• Cardiomyocyte proliferation and differentiation are the principal cellular engines of this process, as shown by transcriptome and chromatin landscape studies during heart development.
• Trabeculation, the formation of myocardial ridges, is controlled by NOTCH1 and NRG1 signaling and is a key morphogenetic output of cardiac muscle tissue growth.
• GATA4 is a master transcriptional regulator of cardiac development and directly influences myocardial growth programs.
• Zebrafish heart regeneration studies demonstrate that cardiomyocyte dedifferentiation and proliferation can reactivate developmental growth programs after injury.
• Dysregulation of cardiac muscle tissue growth is linked to congenital heart defects, heart failure with preserved ejection fraction, and impaired post-infarction repair [2, 1].
Description
GO:0003245, cardiac muscle tissue growth involved in heart morphogenesis, is a Gene Ontology biological process term that captures the developmental expansion of cardiac muscle tissue specifically as it contributes to shaping the heart. This term is not a generic growth category; it is restricted to the morphogenetic window in which cardiomyocytes proliferate, differentiate, and organize into the trabecular, compact, and chambered architecture of the embryonic heart [4, 8]. Researchers studying congenital heart disease, cardiac regeneration, and developmental biology rely on this term to annotate genes whose functions are required for building the heart rather than for maintaining or hypertrophying it after birth. The process is driven by coordinated transcriptional programs, cell-cycle re-entry of cardiomyocytes, and signaling interactions between the myocardium and adjacent tissues such as the endocardium and cardiac jelly [8, 4]. Because the term is defined by its contribution to heart morphogenesis, it excludes pathological cardiac growth and adult hypertrophy, making it a precise annotation target for developmental studies.
cardiac muscle tissue growth involved in heart morphogenesis At A Glance
| GO ID | GO:0003245 |
|---|---|
| GO term | cardiac muscle tissue growth involved in heart morphogenesis |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Developmental growth of cardiac muscle tissue that shapes the heart |
| Related process | Cardiomyocyte proliferation and differentiation during embryogenesis |
| Key signaling pathway | NOTCH1 and NRG1 control of cardiac jelly dynamics and trabeculation |
| Key transcription factor | GATA4 orchestrates cardiac development and myocardial growth programs |
| Disease relevance | Congenital heart defects, heart failure with preserved ejection fraction, and impaired cardiac repair [2, 1] |
What Is GO:0003245?
According to the QuickGO definition, GO:0003245 is the developmental growth of cardiac muscle tissue that contributes to the shaping of the heart. In other words, it covers the period and mechanisms by which cardiac muscle cells increase in number and mass during embryogenesis in a way that physically sculpts the heart, including the formation of trabeculae, compaction of the ventricular wall, and expansion of the chambers [4, 8]. It is a biological process term, and it has no synonyms listed in QuickGO.
Why Is cardiac muscle tissue growth involved in heart morphogenesis Important in Cell Biology?
GO:0003245 is important because it provides a precise ontological handle for the developmental growth phase that builds the heart, separating it from adult cardiac growth and disease-driven remodeling. Defects in this process are directly implicated in congenital heart malformations and in the structural vulnerabilities that predispose to heart failure later in life [6, 8]. Understanding the genes and signals that execute this process also informs regenerative strategies, because reactivating developmental growth programs in adult cardiomyocytes is a major goal of cardiac repair research [3, 1].
• Provides a defined annotation target for genes required for embryonic heart shaping, distinct from adult hypertrophy.
• Links cardiomyocyte proliferation and differentiation to the morphogenetic events that form trabeculae and compact myocardium.
• Supports functional interpretation of transcriptome and chromatin accessibility changes during heart development.
• Helps explain the developmental origins of congenital heart defects and chamber malformations.
• Informs cardiac regeneration research because zebrafish can reactivate cardiomyocyte dedifferentiation and proliferation after injury.
• Connects to angiogenesis and vascular remodeling that support the growing myocardium after myocardial infarction.
• Relevant to heart failure with preserved ejection fraction, where lymphatic and metabolic defects undermine cardiac integrity.
• Guides CRISPR-based disease modeling of cardiac developmental genes in vitro and in vivo [6, 8].
• Provides a framework for comparing developmental growth with pathological growth in disease models.
• Supports bioinformatic enrichment analyses that separate morphogenetic growth from stress-induced cardiac remodeling [4, 6].
What Happens During cardiac muscle tissue growth involved in heart morphogenesis?
Cardiomyocyte proliferation and cell-cycle re-entry
In simple terms: Heart muscle cells multiply to build the growing heart.
During heart morphogenesis, cardiomyocytes re-enter the cell cycle and proliferate, expanding the cardiac muscle tissue that will shape the heart. Transcriptome and chromatin landscape analyses during heart development have demarcated key events in this proliferative window, showing dynamic regulation of cell-cycle and differentiation genes. This proliferative growth is a defining cellular mechanism of GO:0003245, and it is distinct from the later hypertrophic growth of adult cardiomyocytes.
Trabeculation and myocardial patterning
In simple terms: The heart muscle forms ridges and then compacts to build chambers.
Trabeculation is a morphogenetic process in which the myocardium forms ridges that later compact to build the ventricular wall. NOTCH1 and NRG1 signaling control cardiac jelly dynamics and define the building plan for trabeculation, directly linking signaling to cardiac muscle tissue growth during heart morphogenesis. This step is a core output of GO:0003245 because the growth of cardiac muscle tissue physically contributes to the shaping of the heart.
Transcriptional control by cardiac transcription factors
In simple terms: Master switches turn on the genes that build heart muscle.
GATA4 is a master transcriptional regulator that orchestrates cardiac development and beyond, influencing myocardial growth and differentiation programs. The dynamic transcriptome and chromatin landscape of developing cardiomyocytes reveal stage-specific regulatory events that correspond to the growth and morphogenesis phases annotated under GO:0003245. These transcriptional programs ensure that cardiac muscle tissue grows in a coordinated manner that shapes the heart [6, 4].
Interaction with non-myocyte cells and cardiac jelly
In simple terms: Heart muscle growth depends on support cells and the jelly around it.
Cardiac fibroblasts and other non-myocyte populations originate from multiple lineages and contribute to the extracellular environment that supports myocardial growth. NOTCH1 and NRG1 control the dynamics of cardiac jelly, which is essential for trabeculation and for the physical shaping of the heart during morphogenesis. These interactions are integral to GO:0003245 because cardiac muscle tissue growth does not occur in isolation but depends on the surrounding cellular and matrix context [5, 8].
Reactivation in regeneration and repair
In simple terms: Some animals can switch heart muscle growth back on after injury.
Zebrafish heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation, demonstrating that developmental growth programs can be reactivated after injury. Angiogenesis after acute myocardial infarction supports the repair environment and is required for restoring cardiac tissue. These findings connect GO:0003245 to regenerative biology, because the same cellular mechanisms that build the heart during development can be recruited for repair [3, 1].
Key Genes Involved in GO:0003245 cardiac muscle tissue growth involved in heart morphogenesis
The following genes and proteins have been experimentally linked to cardiac muscle tissue growth and heart morphogenesis in the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GATA4 | Master transcription factor orchestrating cardiac development and myocardial growth programs | Central regulator for developmental heart studies and congenital heart defect modeling |
| NOTCH1 | Controls cardiac jelly dynamics and trabeculation building plan | Key signaling node for trabeculation and morphogenesis studies |
| NRG1 | Regulates cardiac jelly dynamics together with NOTCH1 during trabeculation | Ligand-receptor axis for myocardial patterning research |
| MYH7 | Cardiac muscle contractile protein expressed during myocardial development | Marker of cardiomyocyte differentiation in developmental transcriptome studies |
| TNNT2 | Cardiac troponin involved in sarcomere assembly during cardiac muscle growth | Differentiation marker in cardiomyocyte developmental studies |
| NPPA | Cardiac natriuretic peptide expressed in developing myocardium | Marker of trabecular and embryonic cardiomyocyte identity |
| VEGFA | Angiogenic factor supporting vascularization of growing cardiac tissue | Links cardiac muscle growth to angiogenesis in development and repair |
| KDR | VEGF receptor mediating angiogenic signaling in the heart | Target for studying vascular support of myocardial growth |
| CDH5 | Endothelial junction protein in cardiac vasculature | Marker of angiogenesis after myocardial infarction |
| PECAM1 | Endothelial cell adhesion molecule in cardiac vessels | Used to assess vascular density in cardiac repair studies |
| ACTA1 | Actin isoform contributing to sarcomere formation in muscle | Related to contractile apparatus assembly during cardiac growth |
| ACTC1 | Cardiac actin essential for sarcomere function | Differentiation marker in cardiomyocyte developmental studies |
| MYBPC3 | Myosin binding protein C in cardiac sarcomeres | Relevant to contractile maturation during cardiac muscle growth |
| TTN | Titin, a giant sarcomeric protein providing elasticity | Marker of sarcomere maturation in developing cardiomyocytes |
| COL1A1 | Collagen contributing to cardiac extracellular matrix | Relevant to fibroblast-mediated matrix remodeling during heart morphogenesis |
| POSTN | Periostin secreted by cardiac fibroblasts | Marker of fibroblast activation in cardiac tissue remodeling |
| VIM | Vimentin expressed in cardiac fibroblasts | Used to identify fibroblast populations in the developing heart |
How Is cardiac muscle tissue growth involved in heart morphogenesis Regulated?
The process is regulated by developmental signaling pathways and transcriptional networks. NOTCH1 and NRG1 control cardiac jelly dynamics and define the building plan for trabeculation, thereby regulating the morphogenetic growth of cardiac muscle tissue. GATA4 acts as a master transcriptional regulator of cardiac development, coordinating the expression of genes required for myocardial growth and differentiation. Dynamic changes in the cardiomyocyte transcriptome and chromatin landscape demarcate key events of heart development, indicating that stage-specific regulatory programs control when and where cardiac muscle tissue grows. In the context of disease, metabolic and lymphatic defects can undermine cardiac integrity and contribute to heart failure with preserved ejection fraction, highlighting that systemic and microenvironmental factors also influence cardiac tissue homeostasis.
cardiac muscle tissue growth involved in heart morphogenesis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GATA4 | Congenital heart defects and developmental cardiac malformations | Knockout or point-mutation cardiomyocyte differentiation model |
| NOTCH1 | Defective trabeculation and heart morphogenesis | Knockout or conditional knockout in zebrafish or mouse |
| NRG1 | Impaired cardiac jelly dynamics and trabeculation | Knock-in or overexpression in myocardial patterning models |
| VEGFA | Angiogenesis after myocardial infarction | Overexpression or knockout in cardiac repair models |
| ACTC1 | Sarcomere dysfunction and cardiac developmental defects | Point-mutation knock-in in cardiomyocyte models |
Congenital heart defects and developmental malformations
Disruption of cardiac muscle tissue growth during heart morphogenesis can lead to congenital heart defects, including chamber and trabecular malformations. GATA4 is a master regulator of cardiac development, and its dysfunction is linked to developmental cardiac abnormalities. NOTCH1 and NRG1 control trabeculation, and perturbation of this signaling axis can impair the building plan of the heart. These findings establish GO:0003245 as a mechanistically relevant term for congenital heart disease research [6, 8].
Heart failure with preserved ejection fraction
Heart failure with preserved ejection fraction (HFpEF) involves defects in cardiac integrity that can be driven by metabolic and lymphatic dysfunction. Lymphatic endothelial branched-chain amino acid catabolic defects undermine cardiac lymphatic integrity and drive HFpEF, showing that non-myocyte and metabolic factors contribute to cardiac tissue failure. While HFpEF is not a developmental growth disorder, the pathways that maintain cardiac tissue integrity overlap with those that support developmental cardiac muscle growth.
Myocardial infarction and impaired cardiac repair
After acute myocardial infarction, angiogenesis is required to restore the vascular supply to damaged cardiac tissue. Zebrafish studies show that heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation, indicating that reactivation of developmental growth programs can support repair. Failure to reactivate these programs in mammals contributes to scar formation and heart failure, linking GO:0003245 to regenerative medicine [3, 1].
Cardiac fibrosis and fibroblast activation
Cardiac fibroblasts originate from multiple lineages and contribute to the extracellular matrix environment of the heart. During development, fibroblast-derived matrix components support cardiac muscle tissue growth, but in disease, excessive fibroblast activation leads to fibrosis and impaired cardiac function. Understanding the developmental roles of cardiac fibroblasts helps distinguish supportive matrix remodeling from pathological fibrosis.
From cardiac muscle tissue growth involved in heart morphogenesis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is GATA4 required for cardiac muscle tissue growth during heart morphogenesis? | GATA4 knockout or conditional knockout in cardiomyocyte differentiation cultures |
| Does NOTCH1 signaling control trabeculation and cardiac jelly dynamics? | NOTCH1 knockout or knockdown in zebrafish or mouse developmental models |
| Can a disease-associated point mutation in a sarcomeric gene impair cardiac muscle growth? | Point-mutation knock-in in cardiomyocytes or animal models |
| Does overexpression of NRG1 enhance trabeculation or myocardial growth? | NRG1 overexpression in developing heart models |
| Can developmental growth programs be reactivated after cardiac injury? | Zebrafish heart regeneration model with cardiomyocyte lineage tracing |
| Does VEGFA overexpression improve vascularization and cardiac repair after infarction? | VEGFA overexpression in myocardial infarction models |
How to Study the cardiac muscle tissue growth involved in heart morphogenesis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcriptome changes during heart development | Identifying genes driving cardiac muscle tissue growth |
| ATAC-seq | Chromatin accessibility dynamics in developing cardiomyocytes | Mapping regulatory elements of cardiac growth programs |
| EdU/BrdU incorporation | Cardiomyocyte proliferation rate | Quantifying developmental or regenerative cardiac growth |
| Lineage tracing | Origin and fate of cardiomyocytes | Tracking cardiac muscle tissue expansion during morphogenesis |
| In situ hybridization | Spatial expression of cardiac genes | Visualizing trabeculation and myocardial patterning |
| Immunofluorescence | Protein localization in cardiac tissue | Assessing sarcomere and vascular markers |
| Western blot | Protein expression levels in cardiac samples | Validating signaling pathway activation |
| CRISPR knockout screening | Gene requirement for cardiac growth phenotypes | Identifying novel regulators of heart morphogenesis |
Transcriptome and chromatin landscape profiling
RNA-seq and ATAC-seq of developing cardiomyocytes can identify stage-specific gene expression and chromatin accessibility changes that demarcate key events of heart development. These methods allow researchers to map the regulatory programs that drive cardiac muscle tissue growth during heart morphogenesis and to identify candidate genes for functional studies.
Lineage tracing and proliferation assays
Lineage tracing and proliferation markers such as EdU or BrdU incorporation can quantify cardiomyocyte proliferation during heart morphogenesis. Zebrafish heart regeneration studies have used cardiomyocyte dedifferentiation and proliferation assays to show that developmental growth programs can be reactivated after injury. These approaches are essential for linking GO:0003245 to regenerative mechanisms.
Signaling pathway perturbation
Genetic or pharmacological perturbation of NOTCH1 and NRG1 signaling can reveal their roles in cardiac jelly dynamics and trabeculation. Such experiments directly test the morphogenetic functions annotated under GO:0003245 and help identify the signaling requirements for cardiac muscle tissue growth.
Angiogenesis and vascular imaging
Imaging of vascular markers such as CDH5 and PECAM1 can assess angiogenesis in the heart after injury or during development. Because growing cardiac muscle tissue requires vascular support, these methods connect GO:0003245 to the angiogenic processes that sustain myocardial expansion [1, 7].
How CRISPR Can Be Used to Study GO:0003245 cardiac muscle tissue growth involved in heart morphogenesis
Knockout
CRISPR knockout of candidate genes such as GATA4 or NOTCH1 can test their requirement for cardiac muscle tissue growth during heart morphogenesis [6, 8]. Knockout models in cardiomyocyte differentiation cultures or animal embryos allow researchers to observe defects in proliferation, trabeculation, and chamber formation [6, 8].
Point Mutation
Point-mutation knock-in can model disease-associated variants in sarcomeric or transcriptional regulator genes and assess their impact on cardiac muscle growth. Such models are valuable for distinguishing pathogenic variants from benign polymorphisms in developmental cardiac genes.
Knock-in
Knock-in of reporter tags or fluorescent markers into endogenous cardiac genes enables live imaging of cardiomyocyte proliferation and differentiation during heart morphogenesis. Tagged knock-in models can also be used to isolate specific cell populations for transcriptomic analysis.
Overexpression
Overexpression of signaling factors such as NRG1 or VEGFA can test whether enhanced signaling promotes cardiac muscle tissue growth or vascularization [8, 7]. These models are useful for identifying sufficiency relationships in developmental and regenerative contexts [8, 7].
How EDITGENE Supports cardiac muscle tissue growth involved in heart morphogenesis Research
Researchers studying cardiac muscle tissue growth involved in heart morphogenesis-related genes often need to determine whether a candidate gene is causally involved in cardiomyocyte proliferation, trabeculation, or chamber formation. EDITGENE provides CRISPR-based cell model and screening services to support these functional studies.
Contact EDITGENE today to design your custom CRISPR model for cardiac muscle tissue growth involved in heart morphogenesis research.
Frequently Asked Questions About cardiac muscle tissue growth involved in heart morphogenesis
What is GO:0003245?
GO:0003245 is the Gene Ontology biological process term for cardiac muscle tissue growth involved in heart morphogenesis, defined as the developmental growth of cardiac muscle tissue that contributes to the shaping of the heart [4, 8].
What genes are involved in cardiac muscle tissue growth involved in heart morphogenesis?
Key genes include GATA4, NOTCH1, NRG1, and sarcomeric genes such as MYH7 and TNNT2, which have been linked to cardiac developmental growth and trabeculation [6, 8, 4].
How is cardiac muscle tissue growth involved in heart morphogenesis regulated?
It is regulated by developmental signaling pathways such as NOTCH1 and NRG1, which control cardiac jelly dynamics and trabeculation, and by transcription factors such as GATA4 [8, 6].
Why is GO:0003245 important for disease research?
Defects in this process are linked to congenital heart defects, heart failure with preserved ejection fraction, and impaired cardiac repair after myocardial infarction [6, 2, 1].
What is the difference between cardiac muscle tissue growth and cardiac hypertrophy?
GO:0003245 refers to developmental growth during heart morphogenesis, whereas cardiac hypertrophy is a postnatal pathological or physiological enlargement of cardiomyocytes [4, 6].
Can zebrafish be used to study cardiac muscle tissue growth involved in heart morphogenesis?
Yes, zebrafish heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation, making zebrafish a valuable model for studying developmental growth programs.
What signaling pathways control trabeculation during heart morphogenesis?
NOTCH1 and NRG1 signaling control cardiac jelly dynamics and define the building plan for trabeculation.
How can CRISPR be used to study GO:0003245?
CRISPR knockout, point-mutation knock-in, tagged knock-in, and overexpression models can test the requirement and sufficiency of candidate genes in cardiac muscle tissue growth [6, 8, 4].
What methods are used to study cardiac muscle tissue growth involved in heart morphogenesis?
RNA-seq, ATAC-seq, lineage tracing, proliferation assays, and imaging of cardiac and vascular markers are commonly used [4, 3, 1].
What diseases are associated with defects in cardiac muscle tissue growth?
Congenital heart defects, heart failure with preserved ejection fraction, and impaired post-infarction repair are associated with defects in cardiac muscle tissue growth and related processes [6, 2, 1].
Conclusion
GO:0003245, cardiac muscle tissue growth involved in heart morphogenesis, defines the developmental growth of cardiac muscle tissue that physically shapes the heart. It is driven by cardiomyocyte proliferation, transcriptional programs such as GATA4, and signaling pathways such as NOTCH1 and NRG1 that control trabeculation and cardiac jelly dynamics [6, 8, 4]. Understanding this process is essential for congenital heart disease research, cardiac regeneration, and the development of CRISPR-based models that test gene function in heart development [3, 1].
References
- 1. Wu X et al.. 2021. Angiogenesis after acute myocardial infarction.. Cardiovasc Res 117(5):1257-1273 PMID: 33063086
- 2. Guo X et al.. 2025. Lymphatic Endothelial Branched-Chain Amino Acid Catabolic Defects Undermine Cardiac Lymphatic Integrity and Drive HFpEF.. Circulation 151(23):1651-1666 PMID: 40166847
- 3. Jopling C et al.. 2010. Zebrafish heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation.. Nature 464(7288):606-9 PMID: 20336145
- 4. Pawlak M et al.. 2019. Dynamics of cardiomyocyte transcriptome and chromatin landscape demarcates key events of heart development.. Genome Res 29(3):506-519 PMID: 30760547
- 5. Moore-Morris T et al.. 2016. Origins of cardiac fibroblasts.. J Mol Cell Cardiol 91:1-5 PMID: 26748307
- 6. Heuvelmans L et al.. 2025. GATA4: orchestrating cardiac development and beyond.. Cardiovasc Res 121(16):2476-2483 PMID: 41239560
- 7. Braile M et al.. 2020. VEGF-A in Cardiomyocytes and Heart Diseases.. Int J Mol Sci 21(15) PMID: 32722551
- 8. Del Monte-Nieto G et al.. 2018. Control of cardiac jelly dynamics by NOTCH1 and NRG1 defines the building plan for trabeculation.. Nature 557(7705):439-445 PMID: 29743679
